Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $3.80 USD
Change Today -0.0201 / -0.53%
Volume 12.0K
OCRX On Other Exchanges
As of 12:41 PM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

ocera therapeutics inc (OCRX) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/28/14 - $8.10
52 Week Low
04/30/15 - $3.30
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

ocera therapeutics inc (OCRX) Related Businessweek News

No Related Businessweek News Found

ocera therapeutics inc (OCRX) Details

Ocera Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the development and commercialization of OCR-002, which is in Phase IIb trials for the treatment of hyperammonemia and hepatic encephalopathy in patients with liver cirrhosis, acute liver injury, and acute liver failure, as well as in the areas of unmet medical need. The company is headquartered in Palo Alto, California.

16 Employees
Last Reported Date: 03/13/15

ocera therapeutics inc (OCRX) Top Compensated Officers

Chief Executive Officer, President, Secretary...
Total Annual Compensation: $425.0K
Chief Business Officer
Total Annual Compensation: $213.5K
Compensation as of Fiscal Year 2014.

ocera therapeutics inc (OCRX) Key Developments

Ocera Therapeutics, Inc. Announces Executive Changes

Ocera Therapeutics, Inc. announced that effective on June 18, 2015, Jean-Paul Castaigne, M.D. and Lars G. Ekman, M.D., Ph.D., who did not stand for reelection at the annual meeting, ceased to be members of the company's board of directors, and the size of the board was reduced to seven directors. Eckard Weber, M.D. was appointed to the Audit Committee of the board of and Nina Kjellson was appointed to the Compensation Committee of the board, each replacing Dr. Castaigne.

Ocera Therapeutics, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-04-2015 09:00 AM

Ocera Therapeutics, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-04-2015 09:00 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Linda S. Grais, Chief Executive Officer, President, Secretary and Director.

Ocera Therapeutics, Inc. Announces Resignation of Rajiv Patni as the Chief Development Officer Effective as of June 1, 2015

On April 30, 2015, Rajiv Patni, tendered his resignation as the Chief Development Officer of Ocera Therapeutics, Inc. effective as of June 1, 2015. Dr. Patni's resignation was not the result of any disagreements with the Company on any matter relating to the Company's operations, policies or practices.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OCRX:US $3.80 USD -0.0201

OCRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OCRX.
View Industry Companies

Industry Analysis


Industry Average

Valuation OCRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 234.3x
Price/Book 1.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 99.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OCERA THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at